Innovative approaches to lentiviral vector purification: achieving high yields and purity with a chromatography-free process

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Innovative approaches to lentiviral vector purification: achieving high yields and purity with a chromatography-free process

In the field of gene therapy, lentiviral vector (LV) purification stands as a critical yet challenging process. Traditional purification methods often rely on chromatography, which can be costly, complex, and time-consuming, presenting significant challenges in scalability and efficiency. Additionally, maintaining high viral recovery and purity while reducing host cell contaminants is a persistent issue.

IsoTag™ LV offers a chromatography-free solution for LV purification to address these challenges. Utilizing Affinity Liquid Phase Separation (ALPS) coupled with Tangential Flow Filtration (TFF), IsoTag™ LV enables high recovery rates and substantial increase in purity in less than 8 hours. This innovative technology ensures efficient sequestration of LVs, resulting in >50% functional recovery and over 3 log reduction in host cell contaminants.

Attendees will gain insights into how this chromatography-free method simplifies and accelerates the purification process, making it ideal for both small-scale research and large-scale commercial production. The webinar highlights IsoTag™ LV's benefits, including scalability, reduced processing steps, gentle handling, and compatibility with existing equipment, making it a versatile and cost-effective choice for high-quality LV purification.

Learn the advantages of a chromatography-free LV purification processes with IsoTag™ LV
Understand how affinity-based separation technologies coupled with TFF can fit within existing manufacturing processes to achieve enhanced LV recovery with high product quality, while greatly reducing the process time
Learn how Isolere’s platformable process can be used throughout process development to maximize results and minimize use of expensive materials and reagents

Nikki Votaw

Associate Director, R&D at IsolereBio

Nikki Votaw is an Associate Director at Isolere Bio with her work primarily focused on addressing critical challenges in the production of advanced therapeutics, particularly for the applications of cell and gene therapy. She has dedicated several years to pioneering the development of cutting-edge protein reagents designed to optimize and enhance the manufacturing processes involved in these revolutionary therapies. Nikki has spearheaded many collaborations with both academic and industry parties to further develop these products and ensure they reach the right audiences. The products stemming from her work have the potential to create a paradigm shift in downstream processing platforms for viral vectors in addition to profound societal impact by making curative treatments more accessible globally. Nikki received her BS from Georgia Institute of Technology and her PhD from Duke University. Her academic research interests involved developing nanomaterial vaccines and vaccine-related components with an emphasis on creating highly translatable products. Nikki is an author of multiple patents and publications stemming from both academic and industry research.